China CNIPA Showcases Exemplary Cases of Administrative Rulings for Early Resolution of Drug Patent Disputes

WISECODE Take

Many assume China's administrative ruling mechanism for drug patent dispute early resolution covers all legal defenses, but recent exemplary cases show its scope is strictly confined. The mechanism solely determines whether a generic drug falls within patent claims, without adjudicating patent invalidity or prior art defenses. In Case (2022) Guo Zhi Yao Cai No. 0011 (Patent ZL201410468293.6), the CNIPA clarified that patent invalidity must be pursued separately. Meanwhile, Case (2022) Guo Zhi Yao Cai No. 0001 strictly limited the doctrine of equivalents for numerical features such as '0.5% surfactant,' recognizing only standard industry margins of error. Companies outside the pharmaceutical sector or not operating in mainland China remain completely unaffected. For pharma companies expanding into China, litigation tactics must account for dual parallel proceedings, requiring clear boundary definitions in patent portfolios. Actionable steps for operators include: First, when drafting numerical claims, ensure experimental proof of recognized margin of error is well-documented. Second, initiate invalidation proceedings simultaneously alongside administrative resolution requests rather than relying on a single forum. Discerning the distinct parameters of each proceeding is essential for managing patent risks under early resolution regimes.